Positive Phase II Data Reported for Bevacizumab (Avastin) in Cervical Cancer Patients
Two-year survival rate nears 90% (January 15)
The January issue of the International Journal of Radiation Oncology, Biology, and Physics reports results from the Radiation Therapy Oncology Group (RTOG) phase II clinical trial of bevacizumab (Avastin, Genentech) in addition to cisplatin and pelvic radiation in patients with locally advanced cervical cancer.
The addition of bevacizumab to the existing standard of care was safe and showed promising results. The 2- and 3-year overall survival rates were 89.8% and 80.2%, respectively.
The study enrolled 49 patients in 2006–2009. The investigators previously reported that bevacizumab was safe and well-tolerated in combination with cisplatin and radiation therapy in this population. Now the group reports on the secondary efficacy endpoints after a median follow-up period of 3.8 years.
Specifically, the investigators evaluated the addition of bevacizumab (10 mg/kg) every 2 weeks for three cycles during chemoradiation. The overall survival and locoregional control results were favorable in comparison with historical controls of chemoradiation without bevacizumab.
Avastin (bevacizumab) is currently approved for the treatment of metastatic colorectal cancer, advanced non-squamous non–small-cell lung cancer, metastatic kidney cancer, and glioblastoma.
Source: University of Colorado Cancer Center; January 15, 2014.